Effect of Cyclosporine Therapy With Low Doses of Corticosteroids on Idiopathic Nephrotic Syndrome

被引：13

作者：

Griveas, Ioannis ^{[1
]}

Visvardis, George ^{[2
]}

Papadopoulou, Dorothea ^{[2
]}

Nakopolou, Lidia ^{[3
]}

Karanikas, Evaggelos ^{[1
]}

Gogos, Konstantina ^{[1
]}

Stavianoudakis, George ^{[1
]}

机构：

[1] 417 Vet Army Adm Hosp NIMTS, Dept Nephrol, Athens, Greece

[2] Papageorgiou Gen Hosp, Dept Nephrol, Thessaloniki, Greece

[3] Univ Athens, Sch Med, Dept Pathol, GR-11527 Athens, Greece

来源：

ARTIFICIAL ORGANS | 2010年 / 34卷 / 03期

关键词：

Cyclosporine; Nephrotic syndrome; Corticosteroids; Renal function;

D O I：

10.1111/j.1525-1594.2009.00838.x

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Cyclosporine (CyA) has an immunosuppressive effect that might suggest a therapeutic role in idiopathic glomerular conditions. We focused on the optimization of CyA treatment control in patients with idiopathic nephrotic syndrome by using trough-level CyA measurements (C0) and the 2-h postdose levels (C2). Twenty-two patients (14 male, 8 female) with idiopathic nephrotic syndrome and the mean age of 51 +/- 18 months (mean [M] +/- standard deviation [SD]) were enrolled in our study during a period of 10 months (range: 3-18 months). All of the patients received CyA (2-3 mg/kg) in combination with methylprednisolone. In the present study protocol CyA concentrations (C0, C2), renal function, lipid profile, and degree of proteinuria were determined. The mean proteinuria of our patients before treatment was 11 972 +/- 7953 mg/24 H (+/- SD) and the mean creatinine level (Cr) was 0.99 +/- 0.37 mg/dL (+/- SD). Proteinuria decreased significantly already from the first month of therapy with CyA to 3578 +/- 2470 mg/24 H (M +/- SD), and during the whole study period this reduction was significant (0.56 +/- 0.37 gr/24 H (M +/- SD), P < 0.05). At the same time renal function preserved, 1.09 +/- 0.48 mg/dL (M +/- SD). The blood levels of C0 were 135.10 +/- 97.36 ng/mL (M +/- SD) and the blood levels of C2 were 725 +/- 256 ng/mL (M +/- SD) at the first month of therapy. At the same time renal function preserved, 1.09 +/- 0.48 mg/dL (M +/- SD). Total cholesterol levels reduced significantly during study period (276.89 +/- 45.57 to 200.67 +/- 40.27 mg/dL [M +/- SD]). The mean number of antihypertensive medication remained the same. The whole therapeutic protocol did not provoke any kind of side effects and CyA was quite tolerated by our patients. Treatment of idiopathic nephrotic syndrome with low doses of CyA with methylprednisolone leads to remission of proteinuria without deterioration of renal function. Blood levels of C0 for monitoring and treatment of nephrotic syndrome agrees with recent literature, while our study focus on establishing the proper levels of C2 for the treatment of nephrotic syndrome. The efficacy of CyA is combined with safety and tolerance.

引用

页码：234 / 236

页数：3

共 11 条

[1]

Cattran D.C., Alexopoulos E., Heering P., Et al., Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations, Kidney Int, 72, pp. 1429-1447, (2007)

[2]

Midvedt K., Fauchald P., Bergan S., Et al., C2 monitoring in maintenance renal transplant recipients: Is it worthwhile?, Transplantation, 76, pp. 1236-1238, (2003)

[3]

Bokenkamp A., Offner G., Hoyer P.F., Vester U., Wonigeit K., Brodehl J., Improved absorption of cyclosporin A from a new microemulsion formulation: Implications for dosage and monitoring, Pediatr Nephrol, 9, pp. 196-198, (1995)

[4]

Citterio F., Scata M.C., Borzi M.T., Pozzetto U., Castagneto M., C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients, Transpl Proc, 33, pp. 3133-3136, (2001)

[5]

Rosati A., Bertoni E., Zanazzi M., Et al., Neoral dose monitoring with cyclosporine 2-hour post dose levels (C2) in different renal transplant patient age group, Transpl Proc, 33, pp. 3106-3107, (2001)

[6]

Kano M., Kyo K., Yamada Y., Ito S., Ando T., Arisaka O., Comparison between pre- and post-treatment clinical and renal biopsies in children receiving low dose cyclosporine A for 2 years for steroid-dependent nephrotic syndrome, Clin Nephrol, 52, pp. 19-24, (1999)

[7]

Nakahata T., Tanaka H., Tsugawa K., Et al., C1-C2 point monitoring of low dose cyclosporin A given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome, Clin Nephrol, 64, pp. 258-263, (2005)

[8]

Innoue Y., Iijima K., Nakamura H., Yoshikawa N., Two year cyclosporin treatment in children with steroid-dependent nephrotic syndrome, Pediatr Nephrol, 13, pp. 33-39, (1999)

[9]

Ishikura K., Ikeda M., Hattori S., Et al., Effective and safe treatment with cyclosporine in nephrotic children: A prospective, randomised multicenter trial, Kidney Int, 73, pp. 1167-1173, (2008)

[10]

Alexopoulos E., Papagianni M., Tsamelashvilli M., Et al., Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome, Nephrol Dial Transpl, 21, pp. 3127-3132, (2006)

← 1 2 →